PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

brexpiprazole Side Effects

The reactions most often reported to the FDA for brexpiprazole (also sold as Rexulti), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

15,755
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2012 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of brexpiprazole come from 15,755 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 15,755 reports to the FDA Adverse Event Reporting System (FAERS) for brexpiprazole (Rexulti): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

15,755

Reports Mentioning Death

856

5.4% of reports — not proof the medicine caused the death

Hospitalizations

1,926

12.2% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

WEIGHT INCREASED
1,673
AKATHISIA
854
TREMOR
630
ANXIETY
591
TARDIVE DYSKINESIA
590
DEPRESSION
568
SUICIDAL IDEATION
538
FATIGUE
485
INSOMNIA
477
FEELING ABNORMAL
471
DEATH
428
SOMNOLENCE
401
NAUSEA
400
DIZZINESS
380
HEADACHE
359
INABILITY TO AFFORD MEDICATION
359

Who Reports Side Effects

Gender Distribution

Female 9,542 (69%)
Male 4,320 (31%)

Age Distribution

0-17 1,225 (17%)
18-44 2,243 (32%)
45-64 2,190 (31%)
65-74 816 (12%)
75+ 618 (9%)

Reporting Trend by Year

12
13
15
16
17
18
19
20
21
22
23
24
25

Reactions in Death Reports

Top reactions reported in 856 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 427
COMPLETED SUICIDE 120
FALL 50
DISCOLOURED VOMIT 43
UNDERDOSE 37
CARDIAC FAILURE 32
RESPIRATORY ARREST 31
TREMOR 28
HALLUCINATION, AUDITORY 25
PNEUMONIA ASPIRATION 25
INTERNAL HAEMORRHAGE 24
CARDIAC ARREST 18
CARDIO-RESPIRATORY ARREST 16
DYSPHAGIA 15
MARASMUS 15
PNEUMONIA 15

Reactions in Hospitalization Reports

Top reactions in 1,926 reports where hospitalization was an outcome.

Reaction Reports
SUICIDAL IDEATION 217
SUICIDE ATTEMPT 163
CONDITION AGGRAVATED 161
DEPRESSION 126
HOSPITALISATION 116
FALL 101
ANXIETY 93
FATIGUE 83
TREMOR 80
AKATHISIA 77
NAUSEA 71
TREATMENT NONCOMPLIANCE 71
ADVERSE DRUG REACTION 70
DIZZINESS 70
SOMNOLENCE 70
WEIGHT INCREASED 69
DRUG INTERACTION 68

Compare brexpiprazole vs acamprosate →

What the FAERS Data Reveals About brexpiprazole Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 15,755 voluntary reports linked to brexpiprazole and its brand equivalents (Rexulti), spanning 2012 through 2025. Of those, 856 (5.4%) listed death as an outcome and 1,926 (12.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 69% were female and 31% male; age distribution skews toward 18-44, with 2,243 reports in that bracket. The single most reported reaction is weight increased with 1,673 submissions, followed by akathisia and tremor.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.